arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

OMEROS CORP

OMER
$13.26 ▲ +0.12 (+0.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

OMEROS CORP shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $953.6M
Dividend Yield
Revenue Growth None
Op. Margin -176.1%
ROIC 27.5%
FCF / Share $-0.20
Trailing P/E 17.0x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.89M
↓ -67.0%
Net Income Profit after all expenses
$56.06M
↓ -35.2%
Operating Margin Operating profit as % of sales
-176.1%
↓ -189.5%
FCF / Share Free cash flow per share
$-0.20
↑ +67.4%
Long-Term Debt Long-term obligations
$87.90M
↓ -43.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
49
Financial Health
70
Cash Quality
99

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters